Tokyo Tape
Sign in
← PHC Holdings

Half-year report · Q2

6523.TEDINET S100UR3H
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥173.9bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥353.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥166.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥9.2bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income¥4.2bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax¥7.4bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥13.2bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥3.0bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)¥4.1bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥12.9bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥2.5bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥4.0bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income−¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥525.4bnat 2024-09-30Cons.Assets IFRS
Total assets¥564.3bnat 2024-03-31Cons.Assets IFRS
Total assets¥570.4bnat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥398.0bnat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥425.2bnat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥127.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥139.2bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥147.0bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥138.8bnat 2023-03-31dCons.Equity IFRS
Equity (owners)¥127.8bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥139.5bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥147.4bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.0bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥47.0bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥61.4bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.9bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥13.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥41.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥22.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥5.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.1bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥20.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥39.1bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥23.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥32.522024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-102.482023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-19.552023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥32.422024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-102.482023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-19.552023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio24.3%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio25.8%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingrevenue external2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥4.3bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2024-04-01 → 2024-09-30¥48.3bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2024-04-01 → 2024-09-30¥48.3bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.4bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2024-04-01 → 2024-09-30¥62.6bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2024-04-01 → 2024-09-30¥62.6bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2024-04-01 → 2024-09-30¥61.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2024-04-01 → 2024-09-30¥61.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.6bn
—segment totalrevenue2024-04-01 → 2024-09-30¥172.3bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥172.3bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥13.5bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥4.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2023-04-01 → 2023-09-30¥48.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2023-04-01 → 2023-09-30¥48.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2023-04-01 → 2023-09-30¥61.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2023-04-01 → 2023-09-30¥61.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2023-04-01 → 2023-09-30¥55.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2023-04-01 → 2023-09-30¥55.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2023-04-01 → 2023-09-30¥951m
—segment totalrevenue2023-04-01 → 2023-09-30¥165.7bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥165.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥8.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 812
ItemContextValueUnit
Finance income IFRSPrior1YTDDuration463000000JPY
Finance costs IFRSPrior1YTDDuration7675000000JPY
Profit loss before tax IFRSPrior1YTDDuration-3030000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember3548000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember4712000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember4789000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReportableSegmentsMember13050000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReconcilingItemsMember332000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration13383000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember2117000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReportableSegmentsMember2117000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReconcilingItemsMember0JPY
Impairment losses pl IFRSPrior1YTDDuration2118000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember48259000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember61484000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember62561000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember172305000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember1557000000JPY
Revenue from external customers IFRSCurrentYTDDuration173863000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember48259000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember61484000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember62561000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember172305000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember1557000000JPY
Revenue IFRSCurrentYTDDuration173863000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember6361000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember3635000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember3494000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember13491000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-4278000000JPY
Operating profit loss IFRSCurrentYTDDuration9212000000JPY
Finance income IFRSCurrentYTDDuration1414000000JPY
Finance costs IFRSCurrentYTDDuration3215000000JPY
Profit loss before tax IFRSCurrentYTDDuration7411000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember3323000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember4984000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember5661000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReportableSegmentsMember13970000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReconcilingItemsMember340000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration14310000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember56000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass